Facebook Twitter RSS Feed

You are here

Coronary Intervention & Surgery

 - Decision

Most cardiologists who participated in an international web survey used angiography results to assess intermediate stenoses over requesting fractional flow reserve (FFR) measurements or other techniques, contrary to guidelines. This was the case even when resources were not an obstacle.

 - gender, heart

At the heart of things, men and women do react differently to stress. According to a study published in the Oct. 21 issue of the Journal of the American College of Cardiology, the physical impact of mental and emotional stress on the heart and its function differs between men and women.

 - patient

Readmission rates following PCI could be nearly halved, according to research published online Sept. 26 in the Journal of the American Heart Association. The key, researchers wrote, starts with changing clinician behaviors.  

 - hospitalist and patient

Women are almost twice as likely as men to die of any cause in hospital after a STEMI-related primary PCI, according to a study published online Sept. 29 in JAMA: Internal Medicine. This disparity occurs in spite of increased awareness of modifiable risks, researchers wrote.

 - lower arrow

Risk of ischemic stroke within one year of acute MI dropped by 20 percent over a 10-year span in the general Swedish population in a study published online Sept. 18 in Stroke.

 

More Stories

TCT.14: Stents and TAVR, keynote speakers highlighted

Bioresorbable stents, TAVR trials, and keynote speaker Hillary Clinton are high on the must-see list of presentations at this year’s Transcatheter Cardiovascular Therapeutics (TCT) conference, according to director Gregg W. Stone, MD. 

Did guidelines affect post-stent surgical outcomes?

The American College of Cardiology and the American Heart Association released guidelines in 2007 advising physicians to delay surgery following a cardiac stent placement. But, did they help reduce major adverse cardiac events (MACE) following these secondary surgeries? 

Early ticagrelor treatment safe but it doesn’t improve reperfusion

Administering an antiplatelet agent to patients with STEMI in an ambulance was safe but was no more effective at improving coronary reperfusion than treatment in the hospital, based on results from the ATLANTIC trial. Early administration may prevent stent thrombosis, though.

Biodegradable stent matches gold standard for safety, efficacy

A next-generation biodegradable drug-eluting stent proved noninferior to the standard of care in a randomized clinical trial that imposed minimal exclusion criteria, according to results published online Sept. 1 in The Lancet and simultaneously presented at the European Society of Cardiology meeting in Barcelona.

FAME 2, Act 2: FFR-guided PCI keeps its lead at 2 years

PCI guided by fractional flow reserve (FFR) in patients with stable coronary artery disease who were treated with second-generation drug-eluting stents and medical therapy reduced the need for urgent revascularization compared with medical therapy alone, according to two-year results from FAME 2.

Colchicine provides no sweeping benefit after cardiac surgery

Patients undergoing cardiac surgery had mixed results when using colchicine to reduce the incidence of postpericardiotomy syndrome, postoperative atrial fibrillation or postoperative pericardial or plural effusion, according to a study published online Aug. 30 in JAMA.

Trial patients may not reflect larger MI population

Participants enrolled in cardiovascular clinical trials may be a poor representation of patients with MI, according to an analysis published Aug. 27 in JAMA. Researchers found enrollees generally to be healthier, younger and have a better prognosis than eligible nonparticipants.

Hello? Operator? Cardiologists’ communication styles may confuse PCI patients

Joint PCI decision-making may be a best practice, but it appears physicians aren’t encouraging it through their communication styles, according to a paper published online Aug. 25 in JAMA: Internal Medicine.

Meta-analysis gives clarity to bivalirudin’s risk-benefit profile

Compared with heparin, bivalirudin increases the risk of major adverse cardiac events but reduces the risk of bleeding to varying degrees in patients undergoing PCI, a meta-analysis published in the Aug. 16 issue of The Lancet concluded.

High on high-dose aspirin: Bleeding risk influences dosing only slightly

Aspirin dosing patterns after MI seem to favor high doses, regardless of bleeding risks, according to a study published online Aug. 12 in Circulation: Cardiovascular Quality & Outcomes.

Silent & deadly: Cardiac events occur in CAD patients without ischemic, angina symptoms

While coronary artery disease (CAD) patients with both ischemia and angina proved to have higher risks for mortality, 58.2 percent of patients without symptoms died of cardiovascular- or MI-related causes, according to a study published online Aug. 11 in JAMA: Internal Medicine.

Use of quality measures prevents kidney injuries in 1 in 5 PCI patients

Lowering the amount of contrast used and encouraging more oral hydration before and after a PCI procedure reduced contrast-induced acute kidney injury by 21 percent, according to a study published online July 29 in Circulation: Cardiovascular Quality and Outcomes

Timely care for off-hours STEMI still lags in hospitals

Initiatives to provide timely treatment for patients with acute MI overall appear to making an impact but hospitals still have room to improve in their care of patients who present off-hours, an analysis published online July 29 in Circulation: Cardiovascular Quality and Outcomes suggests.

Hybrid coronary revascularization fails to catch on in U.S.

Physicians in the U.S. who treat patients with multivessel coronary disease rarely turn to a hybrid approach for therapy. Over a two-year period, only 0.48 percent of CABG procedures included hybrid coronary revascularization (HCR), reported a study published online July 23 in Circulation.

FDA approves Rebel bare-metal stent

The FDA approved Boston Scientific’s Rebel stent system for treating patients with coronary artery disease. The bare-metal stent consists of a platinum chromium alloy and uses the same design as the company’s Promus Premier stent.

Low-dose heparin in radial PCI rivals bivalirudin at a fraction of its cost

Findings published July 5 in Lancet show low-dose heparin alone to be at least as effective and safe as bivalirudin alone when used in radial PCI in acute MI patients presenting with STEMI, if not more so.

At 2 years, zotarolimus-eluting stents safe, effective in patients with diabetes

Resolute zotarolimus-eluting stents were found to be as safe and effective after two years in small vessels and in patients with diabetes as those with larger diameters or patients without diabetes. In diabetic patients, outcomes were not significantly different between larger and smaller vessel diameters.

Everolimus-eluting stents safe, effective in complex patients at 1 year

In patients with small-vessel coronary artery disease, stenting creates a special set of concerns for providers. A study with XIENCE V everolimus-eluting stents has demonstrated that they are safe and effective in patients with small-vessel disease at one-year follow-up.

Some prasugrel prescribing runs counter to labeling

Prescribing patterns for the anticoagulant prasugrel suggest that there is ample room for improvement.

PCI volume-outcome link holds but threshold is unclear

Volume appears to be key in quality outcomes for PCI, however, the threshold number a provider must perform per year to stay in top form remains elusive, a study published June 17 in Circulation: Cardiovascular Quality and Outcomes stated.